The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Open accessAbstract
BACKGROUND: A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown. METHODS: Applying the mendelian randomisation principle, we used single nucleotide polymorphisms (SNPs) in the gene IL6R to evaluate the likely efficacy and safety of IL6R inhibition for primary prevention of coronary heart disease. We compared genetic findings with the effects of tocilizumab reported in randomised trials in patients with rheumatoid arthritis. FINDINGS: In 40 studies including up to 133,449 individuals, an IL6R SNP (rs7529229) marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala) was associated with increased circulating log interleukin-6 concentration (increase per allele 9·45%, 95% CI 8·34-10·57) as well as reduced C-reactive protein (decrease per allele 8·35%, 95% CI 7·31-9·38) and fibrinogen concentrations (decrease per allele 0·85%, 95% CI 0·60-1·10). This pattern of effects was consistent with IL6R blockade from infusions of tocilizumab (4-8 mg/kg every 4 weeks) in patients with rheumatoid arthritis studied in randomised trials. In 25,458 coronary heart disease cases and 100,740 controls, the IL6R rs7529229 SNP was associated with a decreased odds of coronary heart disease events (per allele odds ratio 0·95, 95% CI 0·93-0·97, p=1·53×10(-5)). INTERPRETATION: On the basis of genetic evidence in human beings, IL6R signalling seems to have a causal role in development of coronary heart disease. IL6R blockade could provide a novel therapeutic approach to prevention of coronary heart disease that warrants testing in suitably powered randomised trials. Genetic studies in populations could be used more widely to help to validate and prioritise novel drug targets or to repurpose existing agents and targets for new therapeutic uses. FUNDING: UK Medical Research Council; British Heart Foundation; Rosetrees Trust; US National Heart, Lung, and Blood Institute; Du Pont Pharma; Chest, Heart and Stroke Scotland; Wellcome Trust; Coronary Thrombosis Trust; Northwick Park Institute for Medical Research; UCLH/UCL Comprehensive Medical Research Centre; US National Institute on Aging; Academy of Finland; Netherlands Organisation for Health Research and Development; SANCO; Dutch Ministry of Public Health, Welfare and Sports; World Cancer Research Fund; Agentschap NL; European Commission; Swedish Heart-Lung Foundation; Swedish Research Council; Strategic Cardiovascular Programme of the Karolinska Institutet; Stockholm County Council; US National Institute of Neurological Disorders and Stroke; MedStar Health Research Institute; GlaxoSmithKline; Dutch Kidney Foundation; US National Institutes of Health; Netherlands Interuniversity Cardiology Institute of the Netherlands; Diabetes UK; European Union Seventh Framework Programme; National Institute for Healthy Ageing; Cancer Research UK; MacArthur Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“genetic evidence suggests that IL-6 may be causal for atherosclerotic cardiovascular disease, 24,25”
From Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genome-wide association studies (GWAS), meta-analysis, exome analysis and single nucleotide polymorphism (SNP) mapping have associated IL-6, IL-6R and gp130 with inflammatory diseases such as RA and coronary artery disease (263–269).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [265]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We also identified associations between IL6R pQTLs and CAD, rheumatoid arthritis and 7 other disease traits (Supplementary Table S12), thereby supporting the findings of the study69.”
From Genetic determinants of plasma protein levels in the Estonian population (2024) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One large study reported a near significant effect ( P = 0.06) of a functional variant causing impaired signalling at the IL-6 receptor with reduced risk of developing diabetes mellitus 44.”
From Type 2 diabetes mellitus and psychological stress — a modifiable risk factor (2017) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“A previous study has shown a link between IL6R and CAD69.”
From Genetic determinants of plasma protein levels in the Estonian population (2024) · cites this paper as [69]
In the citing paper
“Confirming the role of IL-6 in health, in a large Mendelian randomization analysis, the IL6R SNP rs7529229, marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala), was associated with increased circulating IL-6 levels24.”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [24]
In the citing paper
“Variants in the IL6R gene have been found to be associated with increased risk of coronary artery disease24, rheumatoid arthritis, atrial fibrillation, and abdominal aortic aneurysm, and with increased susceptibility to asthma, type 1 diabetes, and depression36,37.”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [24]
In the citing paper
“CETP inhibitors exert their relatively modest cardioprotective effects on the basis that in addition to their HDL-C raising effects, more potent CETP inhibitors also lower apolipoprotein B 22,23,75 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“The approach outlined here to obtaining a scaling estimate has generally held true for lipid-lowering therapies and risk of cardiovascular disease 22,23,40,92 but there are several potential reasons why the derivation of such a scaling for other therapeutic target-indication pairs may pose a challenge.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“However, using SNPs located in CETP associated with HDL-C at genome-wide significant levels in a drug-target MR suggests that modifying HDL-C via CETP, is likely to reduce risk of CHD 23,103 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“CETP 23 variants associate with of CHD; APOA1 117 variants do not associate with risk of CHD”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“Various statistical methods have been proposed to reduce weak instrument bias due to sample overlap and bias due to winner’s curse (see Section 3) 43– 45 .”
From Guidelines for performing Mendelian randomization investigations (2020) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,762
Haploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,563
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Cited by
Sorted by citations
Items 801–900 of 999
The 3p21.31 genetic locus promotes progression to type 1 diabetes through the CCR2/CCL2 pathway
Tran, P. M. H., Purohit, S. B., Kim, E., Satter, K. B., Hopkins, D., Waugh, K., Dong, F., Önengüt-Gümüşcü, S., Rich, S. S., Rewers, M., et al. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100127 · Cited by 7
UEG Week 2018 Oral Presentations
Laursen, S. B., Oakland, K., Laine, L., Bieber, V, Marmo, R., Redondo Cerezo, E., Dalton, H. R., Ngu, J., Schultz, M., Gralnek, I., et al. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618792817 · Cited by 7
Salama, A. D., & Little, M. A. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014111141 · Cited by 6
Statistical Methods for cis-Mendelian RandomizationPreprint
Gkatzionis, A., Burgess, S., & Newcombe, P. J. (2021) · arXiv (Cornell University) · Cited by 6
Mendelian Randomization and Infection: Pitfalls and Promises
Hamilton, F., Butler‐Laporte, G., & Smith, G. D. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf251 · Cited by 5
Wang, Q., Sui, Y., Zhang, L.-T., Meng, N., & Chen, H. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.08.013 · Cited by 7
Triglycerides and T Cells in Cardiovascular Risk
Reilly, N. A., Mulder, J. W. C. M., Dekkers, K. F., Kuipers, T. B., der Zee, L. C. V. V., Mulder, M. T., van Lennep, J. E. R., Jukema, J. W., & Heijmans, B. T. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101359 · Cited by 5
Vatsa, N., Quintana, R. A., Doeberitz, P. K., Onnis, C., Vatsa, S., Newman, N. A., Kauser, T., Rahbar, A., Gold, D. A., Jain, V., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101264 · Cited by 5
de Ruiter, S. C., van Vugt, M., Finan, C., Grobbee, D. E., de Kleijn, D. P. V., Pasterkamp, G., den Ruijter, H. M., Benavente, E. D., Peters, S. A. E., & Schmidt, A. F. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105966 · Cited by 6
Yang, X., Yu, Y., Huang, X., Huang, J., Xiang, Q., & Yu, R. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1681230 · Cited by 5
Yao, Z., Dardari, Z., LaMonte, M. J., Matsushita, K., Ballantyne, C. M., Lima, J. A. C., Vasan, R. S., Simonsick, E. M., Appel, L. J., Cohen, D. L., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.04.015 · Cited by 5
Zu, P., Zhang, L., 王海霞, Zhang, K., He, L., Fan, Y., Zhou, C., 陈云龙, Zhang, Y., Tao, R., et al. (2024) · Environmental Research · doi:10.1016/j.envres.2024.120104 · Cited by 5
Hagag, A. M., Ghanem, O. A., Khalaf, M. M., Ads, M. E., Yassin, Z., Krwash, A., Kormod, M. E., & Albers, G. W. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120448 · Cited by 5
Walker-Smith, T., Joyce, K., Maishman, R., Smartt, H. J. M., Hopkins, E. J., Brierley, R. C. M., Reeves, B. C., Rogers, C. A., Angelini, G. D., & Culliford, L. A. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063268 · Cited by 5
Smith, S. C., & Ascione, R. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108397 · Cited by 5
Woolf, B. A. R., Perry, J. A., Hong, C. C., Wilkins, M. R., Toshner, M. R., Gill, D., Burgess, S., & Rhodes, C. J. (2024) · European Respiratory Journal · doi:10.1183/13993003.02031-2023 · Cited by 5
Qiu, Y., Song, B., Yin, Z., Wang, M., Tao, Y., Xie, M., Duan, A., Chen, Z., Si, K., & Wang, Z. (2024) · European Stroke Journal · doi:10.1177/23969873241265019 · Cited by 5
The physiological paradox: reframing the polypill as a vaccine for cardiovascular disease
Holmes, M. V., & Bhala, N. B. (2013) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2013-202690 · Cited by 5
Fonseca, F. A. H. (2018) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180142 · Cited by 5
Genomic Strategies Toward Identification of Novel Therapeutic Targets
Kessler, T., & Schunkert, H. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_360 · Cited by 5
Rahvar, A., Riesel, M., Graf, T., & Harbeck, B. (2019) · Endocrine · doi:10.1007/s12020-019-01956-3 · Cited by 5
Soliman, A. M., Das, S., & Mahakkanukrauh, P. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210901122359 · Cited by 5
Suzuki, A., Tamamura, T., & Okai, T. (2014) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.37.488 · Cited by 5
Sulfur Mustard Exposure and Cardiovascular Effects: A Review
Karbasi-Afshar, R., Mohammadifard, M., Azdaki, N., Rahnama, P., Saburi, A., & Ghanei, M. (2016) · Trauma Monthly · doi:10.5812/traumamon.34011 · Cited by 5
Kounis, N. G., Koniari, I. C., Soufras, G. D., Chourdakis, E., Despotopoulos, S., Davlouros, P. A., & Hahalis, G. N. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy685 · Cited by 5
Identifying and Validating New Drug Targets for Stroke and Beyond
Plump, A. S., & Smith, G. D. (2019) · Circulation · doi:10.1161/circulationaha.119.042005 · Cited by 4
Commentary: Using human genetics to guide the repurposing of medicines
Bovijn, J., Censin, J. C., Lindgren, C. M., & Holmes, M. V. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa015 · Cited by 4
Inference with many correlated weak instruments and summary statisticsPreprint
Patel, A. R., Burgess, S., Gill, D., & Newcombe, P. J. (2020) · arXiv (Cornell University) · Cited by 4
Specific approaches and limitations in (multi)-omic Mendelian randomization
Cupido, A. J., Zhou, M., Lusis, A. J., & Seldin, M. M. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100619 · Cited by 5
Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide
Sattar, N., Linetzky, B., Ruotolo, G., Verma, S., Sourij, H., Wang, H., Vanderman, K., Wilson, J. M., Griffin, R. M., Stefanski, A., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.04.044 · Cited by 5
Serretti, A., Fabbri, C., Fanelli, G., Baune, B. T., Minelli, A., Serretti, A., Dierssen, M., Maron, E., Potier, M.-C., Gennarelli, M., et al. (2025) · Neuroscience Applied · doi:10.1016/j.nsa.2025.105530 · Cited by 4
Gill, R., Lu, D., Eres, I. E., Lu, J., Cui, J., Wang, C., Yu, Z., Yamawaki, T., Zhou, H., Pei, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64070-1 · Cited by 6
Cardiovascular risk among giant cell arteritis patients
Guédon, A. F., Espitia, O., Beydon, M., Ghrenassia, E., Mirault, T., Messas, E., Tubach, F., Séror, R., Boccara, F., Cohen, A. A., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag034 · Cited by 4
Systemic Inflammation and Recurrence After Atrial Fibrillation–Related Stroke
McCabe, J. J., Harris, K., Gorey, S., Walsh, C., Arnold, M., Marchis, G. M. D., Hervella, P., Iglesias‐Rey, R., Jern, C., Mira, K., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000214701 · Cited by 4
Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome
Jukema, J. W., van Neer, N. J. M., Szarek, M. J., Cobbaert, C. M., Bittner, V., Schwertfeger, M., Bhatt, D. L., Fazio, S., Goodman, S. G., Harrington, R. A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag317 · Cited by 4
Dennis, C. J., He, A. Z., Krishnaraj, A., Quan, A., Teoh, H., Connelly, K. A., Hess, D. A., & Verma, S. (2026) · Circulation Research · doi:10.1161/circresaha.126.327425 · Cited by 4
Panova‐Noeva, M., Koeck, T., Schoelch, C., Schulz, A., Prochaska, J. H., Michal, M., Strauch, K., Schuster, A. K.-G., Lackner, K. J., Münzel, T. F., et al. (2024) · Obesity · doi:10.1002/oby.24014 · Cited by 4
Genetic predisposition to obesity and risk of subclinical atherosclerosis
Shi, J., Hong, J., Qi, L., Cui, B., Gu, W., Zhang, Y., Li, L., Miao, L., Wang, R., Wang, W., et al. (2014) · Gene · doi:10.1016/j.gene.2014.07.059 · Cited by 4
Vidal, S. (2013) · Advances in Pharmacoepidemiology & Drug Safety · doi:10.4172/2167-1052.1000141 · Cited by 4
Zhao, W., Lee, J., Rasheed, A., & Saleheen, D. (2016) · Current Genetic Medicine Reports · doi:10.1007/s40142-016-0103-4 · Cited by 4
Otani, T., Nishihira, K., Azuma, Y., Yamashita, A., Shibata, Y., Asada, Y., & Hatakeyama, K. (2022) · Clinical Pathology · doi:10.1177/2632010x221125179 · Cited by 4
Baquedano, M., de Jesus, S. E., Rapetto, F., Murphy, G. J., Angelini, G. D., Benedetto, U., Caldas, P., Srivastava, P. K., Uzun, O., Luyt, K., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-071629 · Cited by 4
Groenen, A. G., Matveyenko, A., Matienzo, N., Halmos, B., Zhang, H., Westerterp, M., & Reyes‐Soffer, G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117474 · Cited by 4
Inflammation, Lp(a) and cardiovascular mortality: results from the LURIC study
Wissel, S., Scharnagl, H., Kleber, M. E., Delgado, G., Moissl, A. P., Krämer, B. K., & Marz, W. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02609-4 · Cited by 4
Khodarahmi, M., Tabrizi, F. P. F., & Askari, G. (2025) · BMC Nutrition · doi:10.1186/s40795-025-01062-w · Cited by 4
Cardiovascular outcome in patients with adrenal insufficiency—a therapeutic dilemma
Rahvar, A., Riesel, M., Graf, T., & Harbeck, B. (2021) · Endocrine · doi:10.1007/s12020-020-02571-3 · Cited by 4
Martí-Carvajal, A. J., Sanctis, J. B. D., Dayer, M., Martí-Amarista, C. E., Alegría, E., Martín, D. M., Aziz, M. A. A. E., Correa-Pérez, A., Nicola, S., & Parise-Vasco, J. M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014741 · Cited by 4
Inflammation in Cardiovascular Disease: Current Status and Future Perspectives
Fonseca, F. A. H., & Izar, M. C. D. O. (2023) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20230072 · Cited by 5
Importance of sac regression after EVAR and the role of EndoAnchors
Vos, C. G., Fouad, F., DIELEMAN, I. M., Schuurmann, R. C. L., & de Vries, J. P. P. M. (2024) · The Journal of Cardiovascular Surgery · doi:10.23736/s0021-9509.24.12992-8 · Cited by 4
Martí-Carvajal, A. J., Gemmato-Valecillos, M. A., Martín, D. M., Dayer, M., Alegría‐Barrero, E., Sanctis, J. B. D., Parise-Vasco, J. M., Lizardo, R. J. R., Nicola, S., Martí-Amarista, C. E., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014741.pub2 · Cited by 3
McCarty, M. F., O’Keefe, J. H., & DiNicolantonio, J. J. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.03.022 · Cited by 4
Correlation Between Anosmia and Severity Along with Requirement of Tocilizumab in COVID-19 Patients
Silu, M., Mathur, N. P., Kumari, R., & Chaudhary, P. (2021) · Indian Journal of Otolaryngology and Head & Neck Surgery · doi:10.1007/s12070-021-02679-6 · Cited by 4
Liu, K., Xie, Y., Zhao, Q., Peng, W., Guo, C., Zhang, J., & Zhang, L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030392 · Cited by 4
Li, J., Zhang, P., Yi, X., Luo, H., Yu, M., Chen, H., & Wang, C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.977578 · Cited by 5
Oh, S. A., Byun, H., Jang, E.-S., & Jeong, S. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.10.029 · Cited by 4
Precision medicine in myasthenia graves: begin from the data precision
Li, H., Hong, Y., Xie, Y., Hao, H.-J., & Sun, R. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.02.16 · Cited by 4
Coveney, S. A., Murphy, S., O'Donnell, M. J., & Kelly, P. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012825 · Cited by 4
The insulin resistance syndrome
Sattar, N. A., Welsh, P. I., & Preiss, D. (2015) · doi:10.1002/9781118387658.ch23 · Cited by 4
Zheng, J., Tang, H., Lyon, M., Davies, N. M., Walker, V. M., Floyd, J. S., Austin, T. R., Shojaie, A., Psaty, B. M., Gaunt, T. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.23.461369 · Cited by 3
Hamilton, F., Thomas, M., Arnold, D., Palmer, T., Moran, E., Mentzer, A. J., Maskell, N. A., Baillie, J. K., Summers, C., Hingorani, A. D., et al. (2022) · medRxiv · doi:10.1101/2022.07.14.22277638 · Cited by 4
Schmidt, A. F., Finan, C., Chopade, S., Ellmerich, S., Rossor, M. N., Hingorani, A. D., & Pepys, M. B. (2023) · medRxiv · doi:10.1101/2023.08.15.23293564 · Cited by 4
Giannakopoulou, S., Chrysohoou, C. A., Antonopoulou, S., Barkas, F., Vlachogiannis, N., Kravvariti, E., Liberopoulos, E. N., Pitsavos, C., Tsioufis, C., Panagiotakos, D. B., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119212 · Cited by 4
Tan, Y., Zhu, X., Huang, Y., Zhao, C., Cheng, X., Li, J., Zhang, G., Ma, T., Yang, S., & Bai, Y. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.322630 · Cited by 3
Ying, H., Jiang, M., Shi, W., & Xu, X. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106819 · Cited by 3
Bi, J., Liu, X., Zhang, J., & Zhao, L. (2025) · Medicine · doi:10.1097/md.0000000000046718 · Cited by 3
Understanding complex formation of gp130 cytokines for the design of selective therapeutics
Roth, I. R., Fuehring, J. I., & Garbers, C. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2026.120105 · Cited by 3
Silveira, A. L. P. A., de Abreu, D. A., Musto, A. D. L. S., Nali, L. H. D. S., do AMARAL, J. B., Bachi, A. L. L., Neves, L. M., Gil, S. D. S., Santos, F. M., Victor, J. R., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0343214 · Cited by 3
Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis
Mohammadnia, N., Li, L., Ezzat, D., Yu, Z., Raghu, V. K., Halford, J. L., Riksen, N. P., Natarajan, P., Cornel, J. H., Honigberg, M. C., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.1852 · Cited by 3
Epidemiology of interleukin-6: the 30-year follow-up of the 1982 Pelotas (Brazil) birth cohort study
dos Santos, F. S., Oliveira, I. O., Mintem, G. C., Horta, B. L., & Gigante, D. P. (2021) · Annals of Human Biology · doi:10.1080/03014460.2021.1998619 · Cited by 3
The Role of Genetics in Advancing Cardiometabolic Drug Development
Abou-Karam, R., Cheng, F., Gady, S., & Fahed, A. C. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01195-6 · Cited by 3
Sex-specific relationships of inflammatory biomarkers with blood pressure in older adults
Sulicka‐Grodzicka, J., Wizner, B., Zdrojewski, T. R., Mossakowska, M., Puzianowska‐Kuźnicka, M., Chudek, J. T., Więcek, A., Korkosz, M., Caiazzo, E., Maffia, P., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01170-8 · Cited by 3
Ahmad, M. I., Chevli, P. A., Mirzai, S., Rikhi, R. R., Pagidipati, N. J., Slipczuk, L. N., Szklo, M., & Shapiro, M. D. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101310 · Cited by 3
Work-family enrichment: A potential buffer of inflammation among black adults?
Thomas, N. D., Montgomery, S. C., Behers, B. J., Reyes, E., Ledermann, T., & Grzywacz, J. G. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100517 · Cited by 3
Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization
Schooling, C. M., & Zhao, J. (2023) · Current Cardiology Reports · doi:10.1007/s11886-022-01829-8 · Cited by 3
Korotaeva, A. A., Самойлова, Е. В., Жиров, И. В., Роланович, М. Д., Николаевна, Н. С., & Tereschenko, S. N. (2023) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-023-05765-7 · Cited by 3
Tian, J., Zhang, R., Zhu, N., Gu, L., Guo, Y., & Yuan, W. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2202761 · Cited by 3
The Possible Association of IL-6R Gene Polymorphisms in the Development of Diabetic Nephropathy
Ebrat, E., Hejazian, S. M., Ahmadian, E., Vahed, S. Z., Mobasseri, M., & Ardalan, M. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998245369231009111221 · Cited by 3
Yu, S., Wang, M., Yan, M., Wang, B., & Xu, Y. (2023) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2023.10.020 · Cited by 3
Wang, X., Zhao, X., Wang, X., Cao, L., Lu, B., Wang, Z., Zhang, W., Ti, Y., & Zhong, M. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14714 · Cited by 3
Kwok, W. C., Tsui, C. K., Leung, I. S. H., Wong, C. K. E., Tam, T. C. C., & Ho, J. (2024) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-001804 · Cited by 3
Zhao, S. S., & Gill, D. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.04.015 · Cited by 3
Ou, Z., Wang, F., Chen, Y., Liu, X., Ran, B., Yin, Y., & Cui, K. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07622-9 · Cited by 3
Song, S., Qiao, J., Zhao, R., Lu, Y.-J., Wang, C., Zhang, H., Zhang, H.-Y., Li, X., & Wang, C. (2024) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-024-05034-x · Cited by 3
Yin, Z., Zhan, Z., Qiu, Y., Wang, M., Li, J., Song, B., Chen, Z., Wu, J., & Wang, Z. (2025) · Brain and Behavior · doi:10.1002/brb3.70467 · Cited by 3
Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk
Murphy, A. J., Dragoljevic, D., Natarajan, P., & Wang, N. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1830-2147 · Cited by 4
Shuvalova, Y. A., Каминная, В. А., & Каминный, А. И. (2023) · Gene · doi:10.1016/j.gene.2023.147253 · Cited by 5
Are antiretrovirals enough for people living with HIV?
Phillips, A. N., Baker, J., & Lundgren, J. D. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62072-3 · Cited by 3
Study of lipid profile in acute myocardial infarction within 24 hours
Kumar, P., Singh, S., Prasad, S., Yadav, U. P., & Agrawal, P. K. (2018) · Annals of Applied Bio-Sciences · doi:10.21276/aabs.1677 · Cited by 3
Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk
Jones‐O’Connor, M., & Natarajan, P. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0741-4 · Cited by 3
Huang, X., Ye, Q., Zhu, Z., Chen, W., Chen, Y., Li, J., Sun, J., & Ye, Z. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2019.1688810 · Cited by 3
Maxway CRT: improving the robustness of the model-X inference
Li, S., & Liu, M. (2023) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1093/jrsssb/qkad081 · Cited by 6
Liao, K. P., & Solomon, D. H. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38925 · Cited by 3
CANTOS: a seductive song with several verses
Klingenberg, R., & Lüscher, T. F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy363 · Cited by 3
Pugliese, N. R., & Masi, S. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.04.054 · Cited by 3
Research Highlights: Highlights from the Latest Articles in Biomarkers in Medicine
Miyake, M., Giacoia, E. G., Palacios, D. A., & Rosser, C. J. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.36 · Cited by 3
Hallab, A., & The Health and Aging Brain Study (HABS-HD) Study Team (2025) · medRxiv · doi:10.1101/2025.04.14.25325836 · Cited by 3
Maddah, R., Aghili, Z. S., Ghanbari, F., Najafabadi, A. H., & Asgary, S. (2025) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2025.100529 · Cited by 2
The role of interleukin-6 signalling in pleural infection: observational and genetic analyses
Argyriou, A., Robbins, A., Scott, R., Chalmers, J., Wright, H. I. W., Beaumont, R. N., Elvers, K. T., Weedon, M. N., Maskell, N. A., Arnold, D., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105887 · Cited by 2
Panhuis, W. I. H., Thiemann, E., van Dijk, D. M. A. H., Been, B., Jarrett, K. E., Meurs, A., Kooijman, S., Hovingh, M. V., Modder, M., van Os, B. W., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx3794 · Cited by 2
Yan, Q., Zhang, Y., Blue, N. R., Truong, B. M. T., Guerrero, R. F., Honigberg, M. C., Parry, S. I., McNeil, R. B., Simhan, H. N., Chung, J. M., et al. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.10.037 · Cited by 4
Metadata
- Authors
- Swerdlow, D. I.
- Affiliations
- University College London (GB)
- Corresponding author
- Daniel I. Swerdlow
- ORCID
- Daniel I. Swerdlow
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 379
- Issue
- 9822
- Pages
- 1214-1224
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC3316968
- OpenAlex
- W2143727405
- Cited by
- 1,146
- References
- 100
- Citations by year
- 2026: 78 · 2025: 86 · 2024: 94 · 2023: 89 · 2022: 84 · 2021: 110 · 2020: 89 · 2019: 80 · 2018: 74 · 2017: 77 · 2016: 67 · 2015: 56 · 2014: 63 · 2013: 65 · 2012: 32
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Bristol Research (University of Bristol) (publishedVersion, cc-by)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- MRC population health scientist fellowship (G0802432)
- National Institutes of Health (NIH), the MRC, and the British Heart Foundation (BHF (RG/10/12/28456)
- BHF (Schillingford) clinical training fellowship (FS/07/011)
- US National Heart, Lung, and Blood Institute (HHSN268200900009C)
- National Human Genome Research Institute (U01HG005152)
- Cancer Research UK (C1298/A8362, C150/A5660)
- IKEM (Czech Republic) (00023001)
- National Institute for Healthy Ageing (05060810)
- NIH/NHLBI (5215810-55000000041)
- BHF (RG 08/008 and PG/07/133/24260, RG/04/003)
- Netherlands Organisation for Health Research and Development (90700342)
- BHF senior fellowship (FS 05/125)
- British Heart Foundation (RG/10/12/28456)
- contract no. (HHSN268200625226C)
- NHLBI in collaboration with MESA investigators (N01 HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, and RR-024156)
- Wellcome Trust (064947/Z/01/Z and 081081/Z/06/Z)
- National Institute on Aging (1R01 AG23522-01)
- Intramural Research Program of the National Institute on Aging, NIH, Department of Health and Human Services (Z01 AG000954-06, ISGS (R01 NS42733), (R01 NS39987), Z01 AG000015-50)
- European Commission (QLG1-CT-2002-00896)
- Dutch Kidney Foundation (Grant E033)
- GENECURE (FP-6 LSHM CT 2006 037697)
- NIH (grant LM010098)
- The Netherlands Organisation for Health Research and Development (grant 916.761.70)
- European Union's Seventh Framework Programme (FP7/2007-2013)
- NHLBI (RFP-NHLBI-WH-11-10, HL36310)
- Veni grant Organization for Scientific Research (NWO) (2001.064)
- NIH; National Institute on Aging (AG13196)
- MRC (grant NHLBI 33014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- IL-6 receptor, tocilizumab, coronary artery disease, primary prevention, C-reactive protein, fibrinogen, rheumatoid arthritis, genetic variants, monoclonal antibodies
- MeSH terms
- Coronary Disease, Gene Frequency, Genotype, Humans, Phenotype, Genetic Variation, Signal Transduction, Randomized Controlled Trials as Topic, Treatment Outcome, Inflammation Mediators, Receptors, Interleukin-6, Polymorphism, Single Nucleotide, Genetic Association Studies, Mendelian Randomization Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
